Filing Analysis
Xtant Medical Holdings, Inc. announced its financial results for the second quarter of 2026 on August 11, 2026. The filing serves as a formal announcement of the earnings release and provides definitions for non-GAAP financial measures used in their reporting.
📋 Key Facts
- Company reported Q2 2026 financial results on August 11, 2026.
- The company utilizes non-GAAP adjusted EBITDA as a key supplemental metric to measure core operational performance.
- Adjustments to EBITDA include non-cash compensation, foreign currency translation gains/losses, write-offs of distribution agreement deposits, and acquisition/separation-related expenses.
Xtant Medical Holdings, Inc. held its Annual Meeting of Stockholders on August 7, 2026. The meeting resulted in the successful election of six directors and the ratification of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on August 7, 2026.
- Quorum was established with 104,456,998 shares (74.47% of outstanding common stock) present in person or by proxy.
- Six nominees proposed by the Board were elected to serve until the next annual meeting: John K. Bakewell, Jonn R. Beeson, Sean E. Browne, Abhinav Jain, Tyler P. Lipschultz, and Stavros G. Vizirgianakis.
- Stockholders ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
- An advisory vote on executive compensation was approved.
Xtant Medical Holdings reported its first quarter 2026 financial results and announced the date for its 2026 Annual Meeting of Stockholders. The meeting is scheduled for August 7, 2026, which represents a shift of more than 30 days from the prior year's meeting date.
📋 Key Facts
- Reported Q1 2026 financial results on May 13, 2026.
- The 2026 Annual Meeting of Stockholders is set for August 7, 2026.
- Stockholders wishing to submit proposals for the 2026 Annual Meeting must do so by May 23, 2026.
- The company uses non-GAAP adjusted EBITDA as a supplemental performance measure, excluding items like non-cash compensation and acquisition-related expenses.
- Proxy materials are expected to be printed around June 11, 2026.
Xtant Medical Holdings entered into an exclusive U.S. distribution agreement with Dilon Technologies for the FDA-approved HEMOBLAST® Bellows surgical hemostatic agent. The deal includes a $5.0 million upfront exclusivity fee and the hiring of approximately 20 Dilon sales personnel by Xtant.
📋 Key Facts
- Agreement signed on April 10, 2026, granting Xtant exclusive rights to import, market, and sell HEMOBLAST® Bellows in the U.S.
- Xtant paid a $5.0 million exclusivity fee, which is subject to repayment under specific termination circumstances.
- Xtant hired approximately 20 sales personnel from Dilon to support the product's distribution.
- Dilon will continue to manufacture the product in France and supply it to Xtant at a specified transfer price.
- The agreement includes the transition of Dilon's existing U.S. customer base and assignment of existing customer contracts to Xtant.
- There are no minimum purchase requirements for Xtant under the terms of the agreement.
Xtant Medical Holdings, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The filing focuses on the presentation of non-GAAP adjusted EBITDA, which excludes impacts from recent divestitures and acquisitions.
📋 Key Facts
- Financial results reported for the three months and year ended December 31, 2025.
- The company utilized non-GAAP adjusted EBITDA to exclude non-cash compensation and divestiture/acquisition-related expenses.
- Specific divestitures mentioned include the non-core Coflex/CoFix assets and the international hardware business.
- Adjustments were also made for acquisition-related fair value adjustments and separation-related expenses.
Xtant Medical received a $10.7 million payment from Companion Spine, concluding the financial settlement of its previously announced divestiture of Paradigm Spine and certain hardware assets. The final aggregate purchase price reached $21.4 million, and the company used $2.8 million of the proceeds to reduce its term loan debt.
📋 Key Facts
- Received $10.7 million on February 27, 2026, covering an $8.2 million note plus interest and adjustments.
- Total divestiture proceeds increased to $21.4 million from an initial $19.2 million estimate.
- Used $2.8 million of the received funds to prepay a portion of the MidCap Financial Trust term loan.
- Remaining term loan principal balance stands at $11.1 million as of the report date.
Xtant Medical Holdings, Inc. has amended the terms of a promissory note and purchase agreement related to the divestiture of its Coflex/CoFix products and Paradigm Spine GmbH. The amendment extends the maturity date for an $8.2 million unsecured promissory note from January 15, 2026, to January 31, 2026.
🚩 Red Flags
- Extension of maturity date on an unsecured promissory note suggests potential liquidity or cash flow timing issues.
- The extension is very short (only 16 days), indicating imminent pressure to settle the $8.2 million obligation.
- Asset divestitures are often a sign of a company attempting to raise quick liquidity.
📋 Key Facts
- The company previously sold Coflex/CoFix assets and Paradigm Spine GmbH on December 1, 2025.
- Total purchase price for Coflex/CoFix was $17.5 million, with $8.2 million structured as an unsecured promissory note.
- The maturity date of the $8.2 million Note was originally January 15, 2026; it has been extended to January 31, 2026.
- The payment timing for a $1,742,000 estimated positive purchase price adjustment from the Paradigm Spine sale was also moved from Jan 15 to Jan 31, 2026.
Xtant Medical Holdings completed the divestiture of its Coflex/CoFix product lines and its Paradigm Spine GmbH subsidiary to Companion Spine, LLC. The transaction involved a mix of cash and an $8.2 million unsecured promissory note maturing in January 2026.
🚩 Red Flags
- Significant portion of sale consideration ($8.2M) is an unsecured promissory note rather than cash.
- The Companion Spine Note has a very near-term maturity date of January 15, 2026 (approx. 45 days from filing).
- Divestiture involves selling off core product lines and international hardware operations, suggesting a significant shift in business model or liquidity needs.
- The company is using proceeds to pay down existing debt rather than for growth/R&D.
📋 Key Facts
- Completed sale of Coflex and CoFix assets for a total purchase price of $17.5 million (subject to inventory adjustments).
- Coflex/CoFix payment structure: $7.5M previously paid in deposits, $1.8M cash at closing, and an $8.2M unsecured promissory note maturing January 15, 2026.
- Completed sale of 100% equity in Paradigm Spine GmbH (outside US hardware business) for $1.7 million in cash.
- Used approximately $8.0 million of net cash proceeds to prepay a portion of the existing term loan with MidCap Financial Trust.
- Remaining outstanding term loan balance is $14.4 million as of December 1, 2025.
Xtant Medical Holdings, Inc. announced its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
🚩 Red Flags
- Ongoing divestiture of significant assets (Coflex/CoFix and international hardware) may indicate a restructuring or liquidity focus.
- Heavy reliance on non-GAAP adjusted EBITDA which excludes various recurring-type costs like separation and acquisition expenses.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2025.
- Filing date: November 10, 2025.
- The company is currently undergoing a divestiture of its non-core Coflex/CoFix assets and international hardware business.
- Management utilizes non-GAAP adjusted EBITDA as a key performance metric, excluding separation-related expenses and acquisition-related adjustments.
Xtant Medical Holdings, Inc. reported the results of its annual meeting of stockholders held on November 7, 2025. Key outcomes included the election of six directors and the approval of an amendment to increase the available shares under the 2023 Equity Incentive Plan by 12.3 million shares.
🚩 Red Flags
- Increase in equity incentive plan by 12.3 million shares represents a potential dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on November 7, 2025.
- Quorum was established with 96,880,348 shares (69.2% of outstanding) represented in person or by proxy.
- Six nominees for the Board of Directors were successfully elected.
- Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Proposal Three approved an increase of 12,300,000 shares to the 2023 Equity Incentive Plan.
- Advisory votes on executive compensation and frequency of future advisory votes were both approved.
Xtant Medical Holdings, Inc. announced its financial results for the second quarter and first half of 2025. The filing serves as a cover sheet to furnish the quarterly earnings press release and an updated investor presentation.
🚩 Red Flags
- Ongoing divestiture of core segments (Coflex/CoFix) may indicate a strategic pivot or liquidity need.
- Heavy reliance on non-GAAP adjusted EBITDA which excludes significant 'separation-related' and 'acquisition-related' expenses.
📋 Key Facts
- Reported financial results for the three and six months ended June 30, 2025.
- The company is currently undergoing a divestiture of its non-core Coflex/CoFix spinal implants and international business.
- Management utilizes non-GAAP adjusted EBITDA as a key performance measure, specifically excluding separation-related expenses and acquisition-related adjustments.
Xtant Medical Holdings, Inc. announced the scheduling of its 2025 Annual Meeting of Stockholders for November 7, 2025. The filing also outlines specific deadlines for stockholder proposals and director nominations in accordance with SEC rules and company bylaws.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for November 7, 2025.
- Proxy materials are anticipated to be printed on or about September 12, 2025.
- Stockholder proposals under Rule 14a-8 must be received by August 18, 2025.
- Other stockholder proposals and director nominations must be submitted by August 18, 2025.
- Proxy solicitation for non-company nominees requires notice by September 8, 2025, per universal proxy rules.
Xtant Medical Holdings, Inc. announced a significant board reshuffle driven by Nantahala Capital Management, which holds 49.1% of the company's common stock. Two new directors were appointed at the request of Nantahala, while two existing directors resigned as part of an oral understanding with the same majority stakeholder.
🚩 Red Flags
- Significant change in Board composition driven by a single majority shareholder (Nantahala).
- Resignations of two directors linked to an 'oral understanding' with the majority owner.
- Concentrated ownership: Nantahala holds nearly 50% of the company, reducing minority shareholder influence.
📋 Key Facts
- Abhinav (Abi) Jain and Tyler Lipschultz elected to the Board effective August 1, 2025.
- Mr. Jain appointed to Compensation and Nominating/Corporate Governance Committees; Mr. Lipschultz appointed to Audit and Compensation Committees.
- Robert McNamara and Lori Mitchell-Keller resigned from the Board effective August 1, 2025.
- Resignations were pursuant to an oral understanding with Nantahala Capital Management regarding Board composition.
- Nantahala Capital Management is a beneficial owner of 49.1% of the Company's outstanding common stock.
- The board changes occurred following a major share purchase by Nantahala in April 2025, where they acquired 57 million shares at $0.42 per share.
Xtant Medical Holdings, Inc. has entered into agreements to sell its Coflex/CoFix business and its international hardware business (Paradigm Spine GmbH) to Companion Spine, LLC for a combined total of approximately $19.2 million. The transactions are contingent upon the buyer obtaining financing and include significant debt prepayment requirements.
🚩 Red Flags
- Contingency risk: Transactions depend entirely on the Buyer securing financing.
- Counterparty credit risk: A significant portion ($8.2M) of the purchase price is an unsecured promissory note due in late 2025.
- Liquidity pressure: $9.6 million of the proceeds must be used to prepay existing debt (MidCap), limiting net cash retained for operations.
- Execution risk: The closing of both deals is interdependent; if one fails, both fail.
📋 Key Facts
- Sale of Coflex/CoFix Business assets for $17.5 million (subject to inventory adjustments).
- Sale of 100% equity in Paradigm Spine GmbH for $1.7 million.
- Total potential transaction value is approximately $19.2 million.
- $2.5 million non-refundable cash deposit has already been paid by the Buyer.
- The Coflex/CoFix consideration includes an $8.2 million unsecured promissory note maturing Dec 31, 2025.
- Transactions are contingent on the buyer obtaining financing and both deals closing simultaneously.
- Completion of transactions requires a $9.6 million prepayment to MidCap Financial Trust from proceeds.
Xtant Medical Holdings, Inc. announced its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and includes non-GAAP reconciliations.
🚩 Red Flags
- None identified in the provided text (specific loss/revenue figures are contained in Exhibit 99.1 which was not fully provided).
📋 Key Facts
- Reporting period: Three months ended March 31, 2025.
- Announcement date: May 12, 2025.
- The company utilizes non-GAAP adjusted EBITDA as a key performance metric.
- Adjustments to EBITDA include separation-related expenses, non-cash compensation, acquisition-related expenses, and unrealized foreign currency translation gains/losses.
Xtant Medical Holdings, Inc. underwent a significant change in control on April 15, 2025, following a private stock purchase where Nantahala Capital Management, LLC and other investors acquired approximately 52.5% of the company's common stock from OrbiMed Advisors affiliates. This transaction resulted in the company losing its 'controlled company' status on the NYSE American.
🚩 Red Flags
- Significant dilution/ownership shift: Majority owner (OrbiMed) has exited the company entirely.
- Potential for future selling pressure: The company must file a shelf resale registration statement within 30 days to facilitate the sale of the newly acquired shares by Purchasers.
- Change in control threshold adjustment: The company specifically amended credit agreements to prevent the new ownership structure from triggering Change in Control clauses.
📋 Key Facts
- Transaction closed on April 15, 2025.
- Sellers (OrbiMed affiliates) sold approximately 73.1 million shares at $0.42 per share.
- Nantahala Capital Management, LLC purchased 57.0 million shares, resulting in a 49.1% ownership stake.
- The transaction resulted in the Sellers (OrbiMed) no longer being stockholders of the Company.
- The company amended credit agreements with MidCap Financial Trust and MidCap Funding IV Trust to raise the Change in Control threshold from 40% to 49.9%.
- The company is required to file a shelf resale registration statement within 30 days to register the sold shares.
- The company lost its 'controlled company' status under NYSE American rules.
Xtant Medical Holdings announced a major transaction where majority stockholders (affiliates of OrbiMed Advisors) will sell approximately 73.1 million shares to Nantahala Capital Management and other investors at $0.42 per share. This transaction results in Nantahala becoming a significant shareholder with a 49.1% stake, necessitating amendments to existing credit agreements to avoid triggering 'Change in Control' clauses.
🚩 Red Flags
- Significant dilution: The sale of 73.1 million shares at $0.42 per share represents a massive transfer of equity and potential dilution for existing public shareholders.
- Concentrated Ownership: A single entity (Nantala) will control nearly half (49.1%) of the company's voting power.
- Credit Agreement Restructuring: The need to amend 'Change in Control' thresholds suggests the transaction would have otherwise triggered defaults or restrictive covenants under existing debt terms.
📋 Key Facts
- Sellers (OrbiMed affiliates) to sell ~73.1 million shares of common stock.
- Transaction price is $0.42 per share.
- Nantahala Capital Management will purchase 57.0 million shares, resulting in a 49.1% ownership stake post-transaction.
- The Company entered into a Registration Rights Agreement to register the resale of these shares within 30 days of closing.
- Credit agreements were amended (Amendment No. 2) to raise the 'Change in Control' threshold from 40% to 49.9% to accommodate Nantahala's new ownership level.
Xtant Medical Holdings, Inc. announced its financial results for the three months and full year ended December 31, 2024. The filing serves as a formal announcement of quarterly/annual earnings via an attached press release.
🚩 Red Flags
- Frequent use of non-GAAP adjustments (separation costs, legal settlements) can sometimes mask underlying operational inefficiencies or recurring losses in micro-cap companies.
📋 Key Facts
- Reporting period: Three months and fiscal year ended December 31, 2024.
- Announcement date: March 6, 2025.
- The company utilizes non-GAAP adjusted EBITDA as a key performance measure.
- Adjustments to EBITDA include separation related expenses, legal settlements, non-cash compensation, and acquisition-related items.
Xtant Medical Holdings, Inc. announced its financial results for the three and nine months ended September 30, 2024. The filing serves as a formal announcement of the quarterly earnings release.
🚩 Red Flags
- None identified in the provided text (the filing is a standard earnings announcement).
📋 Key Facts
- Financial results were reported for the period ending September 30, 2024.
- The company utilizes non-GAAP adjusted EBITDA to supplement GAAP financial statements.
- Adjusted EBITDA reconciliations include add-backs for separation related expenses, legal settlements, and non-cash compensation.
Xtant Medical Holdings is providing updated historical financial statements and pro forma information related to its June 2023 acquisition of Surgalign Holdings, Inc. This filing is a regulatory requirement to support an upcoming Form S-3 registration statement.
📋 Key Facts
- The company acquired substantially all assets/liabilities of Surgalign Holdings, Inc. on August 10, 2023.
- Filing provides updated financial statements for the six months ended June 30, 2023 and 2022 (unaudited).
- Includes unaudited pro forma condensed combined statement of operations for the year ended December 31, 2023.
- The purpose of this disclosure is to satisfy requirements for an intended Form S-3 registration statement.
Xtant Medical Holdings, Inc. entered into a securities purchase agreement for a $5.0 million private placement of 7,812,500 shares at $0.64 per share to an existing institutional investor. The proceeds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Dilutive financing: Issuance of 7.8M shares at $0.64 per share likely represents significant dilution for existing shareholders.
- Liquidity pressure: Use of proceeds is earmarked for 'working capital,' suggesting immediate cash needs.
- Restrictive covenants: Includes a prohibition on issuing certain securities or variable rate transactions for up to 6 months.
📋 Key Facts
- Private placement of 7,812,500 shares of common stock.
- Issue price: $0.64 per share.
- Gross proceeds expected to be $5.0 million (before fees).
- Closing date expected on or about August 9, 2024.
- Includes a registration rights agreement requiring the company to file a shelf resale registration statement within 30 days of closing.
- Contains liquidated damages provisions if the company fails to meet filing deadlines for the registration statement.
Xtant Medical Holdings, Inc. announced its financial results for the second quarter of 2024, reporting significant revenue growth. The filing serves as a vehicle to furnish the quarterly earnings press release.
🚩 Red Flags
- None identified in this specific filing (standard earnings release).
📋 Key Facts
- Reported revenue growth of 48% for the second quarter of 2024 according to the referenced press release.
- Financial results cover the three and six months ended June 30, 2024.
- The company utilizes non-GAAP adjusted EBITDA as a key supplemental metric to evaluate core operational performance.
Xtant Medical Holdings, Inc. held its 2024 annual meeting of stockholders on July 23, 2024. The results included the election of six directors and the ratification of Grant Thornton LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on July 23, 2024.
- Quorum was established with 105,850,527 shares (81.25% of outstanding common stock) present in person or by proxy.
- Six nominees proposed by the Board were elected to serve until the next annual meeting.
- Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Stockholders approved executive compensation on an advisory basis (Say-on-Pay).
- Total shares outstanding at record date: 130,268,590.
Xtant Medical Holdings, Inc. announced its financial results for the first quarter ended March 31, 2024. The company reported significant revenue growth of 55% and has raised its full-year 2024 revenue guidance.
📋 Key Facts
- Reported Q1 2024 revenue growth of 55%.
- Raised full-year 2024 revenue guidance.
- Financial results for the three months ended March 31, 2024, were furnished via Exhibit 99.1.
- Company utilizes non-GAAP adjusted EBITDA as a key performance measure.
Xtant Medical Holdings, Inc. announced its financial results for the three months and full year ended December 31, 2023. The filing includes a press release highlighting record full-year revenue of $91.3 million.
📋 Key Facts
- Reported record full-year 2023 revenue of $91.3 million.
- Financial results cover the three months and year ended December 31, 2023.
- Company utilizes non-GAAP measures including adjusted EBITDA and organic revenue growth to supplement GAAP results.
Xtant Medical Holdings, Inc. has entered into amended and restated credit agreements with MidCap Financial Trust and MidCap Funding IV Trust. The restructuring includes a $17 million secured term loan facility and a $17 million revolving credit facility, both maturing in March 2029.
🚩 Red Flags
- High interest rate structure (SOFR + margin) typical of distressed or high-risk micro-cap financing.
- Restrictive covenants regarding revenue, liquidity, and ability to incur additional debt or engage in M&A.
- First-priority liens on all substantial assets provide significant leverage to lenders.
📋 Key Facts
- Term Credit Agreement: $17,000,000 principal amount (previously funded) plus an additional $10,000,000 tranche available at lender discretion.
- Revolving Credit Agreement: Up to $17,000,000 revolving facility based on a borrowing base of accounts receivable and inventory.
- Maturity Date: March 1, 2029.
- Interest Rates: SOFR + 6.50% for the Term Loan; SOFR + 4.50% for the Revolving Facility (subject to a 2.50% floor).
- Collateral: First-priority liens on substantially all assets, including inventory, equipment, accounts, and intellectual property.
- Covenants: Includes minimum net product revenue levels and minimum liquidity requirements.